Status:
COMPLETED
Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal
Lead Sponsor:
Windber Research Institute
Conditions:
Heart Diseases
Cardiovascular Diseases
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The purpose of this study is to characterize changes in gene and protein expression in peripheral blood in patients with, or at risk for, heart disease during an intensive lifestyle modification progr...
Detailed Description
This project will use an integrated approach that examines DNA variation and the functional products of genes at both the messenger RNA (mRNA) and protein levels to provide a global view of molecular ...
Eligibility Criteria
Inclusion
- diagnosis of coronary artery disease (CAD)
- stable angina
- angioplasty
- evidence of \>50% luminal narrowing on coronary angiogram
- acute myocardial infarction
- bypass surgery
- stent placement OR
- two or more CAD risk factors
- systolic pressure \>140 mm Hg or diastolic pressure \>90 mm Hg)
- high total cholesterol (\>200 mg/dL)
- physician diagnosed diabetes
- body mass index (BMI) \>30
- family history of heart disease in parents or siblings
- 21 years of age or older
- mentally competent to provide informed consent
Exclusion
- known history of autoimmune disease
- systemic/chronic disease requiring chemotherapy or long term treatment
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
422 Patients enrolled
Trial Details
Trial ID
NCT01805492
Start Date
January 1 2000
End Date
February 1 2009
Last Update
March 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Windber Medical Center
Windber, Pennsylvania, United States, 15963